Sequential Decitabine and Carboplatin Induced Stabilisation of Tumour Burden in a Patient with Immunotherapy-Resistant Metastatic Melanoma
暂无分享,去创建一个
L. Hesson | R. Vilain | N. Bowden | R. Levy | M. Graves | A. Westhuizen | N. Knoblauch
[1] J. Wargo,et al. A phase II study of oral azacitidine (CC-486) in combination with pembrolizumab (PEMBRO) in patients (pts) with metastatic melanoma (MM). , 2017, Journal of Clinical Oncology.
[2] N. Bowden,et al. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma , 2018, BMC Cancer.
[3] R. C. Poulos,et al. CpG methylation accounts for genome-wide C>T mutation variation and cancer driver formation across cancer types , 2017, bioRxiv.
[4] Anushi Shah,et al. Differential DNA repair underlies mutation hotspots at active promoters in cancer genomes , 2016, Nature.
[5] D. Matei,et al. Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study , 2015, PloS one.
[6] Xiaobing Fu,et al. Decitabine: a promising epi-immunotherapeutic agent in solid tumors , 2015, Expert review of clinical immunology.
[7] D. Matei,et al. Decitabine reactivated pathways in platinum resistant ovarian cancer , 2014, Oncotarget.
[8] L. Bracci,et al. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer , 2013, Cell Death and Differentiation.
[9] D. Matei,et al. Epigenetic resensitization to platinum in ovarian cancer. , 2012, Cancer research.
[10] R. Bast,et al. Phase 1b‐2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum‐resistant or platinum‐refractory epithelial ovarian cancer , 2011, Cancer.
[11] D. Matei,et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum‐resistant, epithelial ovarian cancer , 2010, Cancer.
[12] Z. Siddik,et al. Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.
[13] L. Einhorn,et al. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. , 1987, The New England journal of medicine.
[14] D. Guerry,et al. WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.